R&D Group Head Asahi KASEI Corporation Fuji, Shizuoka, Japan
This study addresses the need for sustained release of biologics to reduce injection frequency and lessen patient burden. PLGA particles, a common API carrier, denature biologics due to organic solvents and acidic microenvironments. Hyaluronic acid nanogel (HA nanogel), composed of cholesterol-modified hyaluronic acid, was investigated as an alternative carrier. HA nanogel encapsulated biologics by simple mixing in aqueous solution, preventing denaturation. It formed in-situ depots under physiological conditions, enabling sustained subcutaneous release. Pharmacokinetics studies showed prolonged mean residence time for model peptide and protein, offering a versatile platform for sustained biologic release.
Learning Objectives:
Upon completion, participant will be able to learn a cutting-edge approach using a novel pharmaceutical excipient to modulate release profiles of biologics and its advantages over PLGA particles.
Upon completion, participant will be able to learn release mechanism of a novel pharmaceutical excipient HA nanogel.
Upon completion, participant will be able to learn IVIVC of a novel pharmaceutical excipient HA nanogel.
